VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
#Acquisition
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
undefined
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
undefined
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
undefined
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
#Acquisition #Expand #Partners
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
undefined
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
undefined
13 Best Biotech Penny Stocks To Buy Now
undefined
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
undefined
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
#Management Changes #Layoffs
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
undefined
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
#Investment
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
undefined
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
undefined
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
undefined
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
undefined
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
undefined
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
undefined
VBL Therapeutics Announces Workforce Reduction
undefined
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
undefined
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low
undefined
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low
#Investment
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
#Customers
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
#Investment
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
#Customers
VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer
#Investment
Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036
#Investment #Management Changes
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting
#Customers
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
#Partners
VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
#Partners #Investment
VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today
#Partners
VBL Therapeutics reports promising data for anti-cancer gene therapy VB-111
undefined
VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.
#Customers
VBL Therapeutics raising $18.75m in Nasdaq offering
#Investment
VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
#Investment
Vascular Biogenics raising $22m in Nasdaq offering
#Investment
VBL Therapeutics' brain cancer drug succeeds in mid-stage study
#Investment #Expand